| Press Releases

Worldwide Clinical Trials Selects Medidata to Streamline Clinical Site Reimbursements Across the Globe

Medidata’s end-to-end Payments Cloud to help Worldwide change the CRO experience – accelerating accurate, timely payments

NEW YORK – July 12, 2017  Medidata (NASDAQ: MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, today announced that after an exhaustive 18 month selection process which encompassed all of the leading site payments technologies, Worldwide Clinical Trials (Worldwide) has selected Medidata Payments Cloud to streamline accurate, timely payments on behalf of their clinical trial sponsors.

Medidata Payments Cloud is the industry’s only global site payment technology that’s driven by EDC. Focused on executing predictable, successful studies across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID) and rare diseases, Worldwide will leverage Medidata Payments Cloud to automatically trigger, calculate and disburse payments directly into an investigative site’s bank account. These capabilities will further enable Worldwide to transform the CRO experience for sponsors and sites – shortening payment cycle times, increasing accuracy and eliminating hours allocated to reconciliation and reporting.

“Worldwide’s success as a CRO is down to our ability to partner successfully with our trial sponsors and sites – going above and beyond in the delivery, operation and support of all of our services,” said Anthony Doyle, Chief Financial Officer, Worldwide. “Medidata Payments Cloud stood out as a truly end-to-end solution, driven by EDC, and for the opportunity it provides us to reimburse sites as quickly and accurately as possible – important as we invest in processes and technology that help Worldwide continue to stand out as a top-ranked performer for service and customer loyalty.”

Medidata’s unified, cloud-based platform, including industry leading EDC Rave which is fully integrated with Payments, is the only end-to-end solution on the market with full support for global tax calculations and disbursements to ensure accurate and timely payments. With on-demand funding, Medidata Payments enables organizations to establish a more robust financial strategy. In addition, companies are able to save significant resources usually spent on reconciliation thanks to real-time access to accrual and forecasting reports.

“Timeliness and accuracy in payments are critical to the success of contract research organizations, and achieving both can be incredibly challenging,” said April Mulroney, Managing Director of Payments at Medidata. “We’re proud that Worldwide has selected Medidata Cloud Payments, which will help them create an industry-leading site payment operation, ensuring sites are easily paid on time, and reporting to sponsors is accurate and timely.”

About Medidata

Medidata is reinventing global drug and medical device development by creating the industry’s leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including more than 850 global pharmaceutical companies, innovative biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.

The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world’s top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers—from study design and planning through execution, management and reporting.

About Worldwide Clinical Trials

Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase and post-approval, we provide world-class, full-service drug development services. With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID) and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit Worldwide.com.

Media Contact

Medidata Contacts
Investor: Anthony D’Amico, +1 732-767-4331, adamico@mdsol.com
Media: Erik Snider, Medidata Solutions, +1 646-362-2997, esnider@mdsol.com

Worldwide Clinical Trials
Media: Sherri Stuart, Sherri.Stuart@worldwide.com

Recent Press Releases


Our extensive collection of scientific articles and papers